Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Product deliveries scheduled in Q3 of 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
The Global Medical Countermeasures Platform will provide equal access safe, high-quality, cost-effective medical countermeasures to the world
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Lonza launches the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation developed to optimize and streamline CAR T-cell manufacturing
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
These initiatives aim to improve access to healthcare for rare disease patients
Concept Medical’s manufacturing arm has reduced its carbon footprint via in-house efficiency improvement programmes & green infrastructure
Subscribe To Our Newsletter & Stay Updated